ADMA Biologics, Inc. (ADMA) shares price almost doubled since company announced that the FDA approved its Asceniv, intravenous immunoglobulin product for the treatment of primary humoral immunodeficiency disease (PIDD), in adults and adolescents ages from 12 to 17. PIDD is a collective term for numerous diseases that occur due to defects in the body’s immune …Read More
Tag Archives: ADMA Biologics